uniQure NV (NASDAQ:QURE) shares fell 1.9% on Thursday . The stock traded as low as $7.52 and last traded at $7.57, with a volume of 113,287 shares traded. The stock had previously closed at $7.72.

Several research firms have weighed in on QURE. Jefferies Group reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. Chardan Capital reiterated a “buy” rating on shares of uniQure NV in a research report on Thursday, April 14th. Leerink Swann reiterated a “buy” rating on shares of uniQure NV in a research report on Sunday, June 12th. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of uniQure NV in a research report on Monday, June 13th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. uniQure NV has a consensus rating of “Buy” and an average target price of $30.80.

The company’s market capitalization is $185.89 million. The firm’s 50-day moving average is $9.49 and its 200-day moving average is $12.98.

uniQure NV (NASDAQ:QURE) last released its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.10. Equities analysts predict that uniQure NV will post ($3.14) EPS for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.